Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as an injectable solution for subcutaneous use. It is indicated for prophylaxis of deep vein thrombosis in surgical patients, treatment of pulmonary embolism, and anticoagulation during hemodialysis procedures.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. We adhere to stringent quality standards and provide comprehensive support for regulatory documentation.

Ledraxen, a low molecular weight heparin, is used in clinical settings that require inhibition of clot formation.

- Deep vein thrombosis (DVT) prophylaxis: prevents clot development in patients undergoing surgery or immobilization. - Pulmonary embolism treatment: facilitates resolution of existing emboli and reduces recurrence risk. - Anticoagulation during hemodialysis: maintains circuit patency by preventing thrombus formation.

Enoxaparin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site bruising or hematoma: localized bleeding under the skin. - Minor bleeding: such as epistaxis, gum bleeding, or easy bruising. - Nausea or vomiting: gastrointestinal discomfort. - Headache or dizziness: transient neurologic symptoms. - Elevated liver enzymes: mild, transient hepatic changes.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk. - Major hemorrhage: internal bleeding that may be life‑threatening. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Severe allergic reaction: anaphylaxis or angioedema. - Thrombosis despite therapy: rare clot formation while on treatment.

Before initiating Ledraxen, clinicians should evaluate several safety considerations to minimize bleeding risk and other complications.

- Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Surgery or invasive procedures: discontinue before to reduce peri‑operative bleeding. - Concomitant antiplatelet therapy: increase monitoring for additive bleeding. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin can interact with other medicines, affecting its anticoagulant effect or increasing bleeding potential.

Major Interactions (Avoid): - Other therapeutic anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulation may cause severe bleeding. - Systemic thrombolytics (e.g., alteplase): heightened risk of major hemorrhage. - High‑dose NSAIDs or aspirin: potentiate gastrointestinal and systemic bleeding. - Neuraxial anesthesia or spinal puncture: increased chance of spinal hematoma.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., clopidogrel, ticagrelor): monitor for bleeding signs. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: may modestly raise bleeding risk. - Renally cleared drugs that affect coagulation (e.g., certain antibiotics): observe anti‑Xa activity.